Downstream sample preparation for subsequent quality attribute analysis represents “a significant bottleneck in process development for non-antibody biologics,” wrote Kevin Brower, PhD, global head of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback